INDICATIONS: Treatment of systemic fungal infections such as blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Its use is restricted to cases where safer and more effective alternatives are not available, or when, after evaluating the patient, the benefits outweigh potential risks. Treatment of Cushing’s syndrome in cases where no other alternatives exist, under strict medical supervision.

DOSAGE: Administered orally, 200 mg once daily, taken with food to increase absorption and reduce gastrointestinal discomfort. The dose may be increased to 400 mg daily if an adequate response is not achieved.

Pediatric Patients: Children over 2 years: recommended 3 mg per kg of body weight per day.

CONTRAINDICATIONS: Micosin® is contraindicated in patients hypersensitive to this medication. Co-administration of ketoconazole with astemizole, cisapride, corticosteroids, triazolam, cyclosporine, oral anticoagulants, and terfenadine is contraindicated. Its use is not recommended during pregnancy and lactation.

PRECAUTIONS: Liver function tests are recommended before starting treatment and periodically during therapy. Concomitant use with hepatotoxic substances such as alcohol and paracetamol should be avoided. A disulfiram-like reaction may occur in patients taking ketoconazole after consuming alcohol. The effectiveness of oral contraceptives may be reduced.

INTERACTIONS: Ketoconazole inhibits the metabolism of a number of drugs by acting on the CYP3A4 isoenzyme of the hepatic microsomal P450 system. This leads to increased plasma levels of terfenadine, prolonging the QT interval. Similarly, it reduces the clearance of astemizole, which may cause arrhythmias, tachycardia, cardiac arrest, and death. Astemizole should be discontinued at least one week before starting ketoconazole therapy. Ketoconazole reduces the clearance of cisapride; concomitant use has been associated with QT prolongation and torsades de pointes. Ketoconazole can induce disulfiram-like reactions; alcohol should be avoided during treatment and for at least 48 hours after discontinuation. Concomitant administration of ketoconazole and indinavir increases the antiviral’s AUC by 68%. Ketoconazole dramatically inhibits the hepatic metabolism of triazolam and midazolam; simultaneous use should be avoided. Other benzodiazepines affected include alprazolam and estazolam. Ketoconazole requires an acidic gastric pH for absorption; drugs that reduce gastric acid secretion or alkalinize the stomach significantly reduce its bioavailability, including antacids, antimuscarinics, H2 antihistamines, and proton pump inhibitors. Sucralfate also reduces ketoconazole absorption by 20%. Ketoconazole may decrease the clearance of corticosteroids such as prednisolone and methylprednisolone, increasing plasma concentrations. It also increases cyclosporine plasma levels. Ketoconazole can reduce the clearance of calcium channel blockers (e.g., diltiazem, felodipine, verapamil) by inhibiting CYP3A4 metabolism. Concomitant use with tacrolimus may increase tacrolimus blood levels. Co-administration with ritonavir results in 3–4 fold increases in ketoconazole concentrations; therefore, doses >200 mg/day are not recommended with ritonavir.

PREGNANCY AND LACTATION: Preclinical data indicate that ketoconazole crosses the placenta and is teratogenic. It should only be used during pregnancy when the therapeutic need for the mother outweighs the risk to the fetus. As ketoconazole is excreted in breast milk, breastfeeding should be discontinued during treatment.

ADVERSE REACTIONS: Nausea, vomiting, and abdominal pain have been reported; these are usually mild and can be minimized if the drug is taken with food, which also improves bioavailability. Rarely, hepatotoxicity occurs. These effects are reversible upon discontinuation of treatment.

Oral suspension 400 mg/80 mg /5mL: 120 mL bottle + measuring spoon.

COMPOSITION:

Each coated tablet contains: Trimethoprim 160 mg and Sulfamethoxazole 800 mg. (CO-TRIMOXAZOLE).

Each 5 mL teaspoon contains:

trimethoprim 80 mg and sulfamethoxazole 400 mg. (CO-TRIMOXAZOLE)

INDICATIONS: Broad-spectrum chemobactericide, recommended for: Acute and chronic infections of the urinary tract, caused by E. coli, P. mirabilis or Klebsiella pneumoniae. Prophylaxis in women with multiple reinfections

Acute and chronic bacterial prostatitis.

Acute gastroenteritis, caused by Salmonella, Shigella and E. coli.

Typhoid, including resistant to chloramphenicol and ampicillin.

Otitis media and exacerbations of chronic bronchitis, caused by Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae.

Pneumocystis carinii pneumonia in patients with AIDS.

DOSE: Meprimforte can be administered with or without food.

The usual dose is one Meprimforte tablet every 12 hours for 7 to 14 days, depending on the infection. In uncomplicated cystitis in women: one tablet every 12 hours for 3 days. In bacterial gastroenteritis: 1 tablet every 12 hours for 5 days. In prevention of recurrences of urinary tract infections ½ tablet 3 times a week for several months.

Dose in adults and children over 12 years: 1 tablet every 12 hours

Dose in children: 8 mg/kg/day of the trimethoprim dose or 40 mg/kg/day of the sulfamethoxazole dose, divided every 12 hours.

CONTRAINDICATIONS AND PRECAUTIONS:

Patients hypersensitive to cotrimoxazole.

Term pregnant women.

Under 2 months of age.

Cotrimoxazole is not recommended during pregnancy or lactation.

It should not be co-administered with metheneamine.

COMPOSITION: Each 5 mL teaspoon contains: Trimethoprim 40 mg and Sulfamethoxazole 200 mg. (CO-TRIMOXAZOLE)

INDICATIONS: The main indications: Acute and chronic infections of the urinary tract, caused by E. coli, P. mirabilis or Klebsiella pneumoniae. Prophylaxis in women with multiple reinfections

Acute and chronic bacterial prostatitis.

Acute gastroenteritis, caused by Salmonella, Shigella and E. coli.

Typhoid, including resistant to chloramphenicol and ampicillin.

Otitis media and exacerbations of chronic bronchitis, caused by Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae.

Pneumocystis carinii pneumonia in patients with AIDS.

DOSE: Meprim can be administered with or without food.

Gastrointestinal infections: 40 – 60 / 8 – 10 mg/kg/day divided into 2 doses.

Airway and Urinary Tract Infections: 20 -30 /4 -6 mg/kg/12 hours for 10 days.

CONTRAINDICATIONS and PRECAUTIONS:

Patients hypersensitive to cotrimoxazole.

Term pregnant women.

Under 2 months of age.

Cotrimoxazole is not recommended during pregnancy or lactation.

It should not be co-administered with metheneamine.

Anti-arthritis Anti-inflammatory

COMPOSITION

Meloxicam 15mg

Glucosamine sulfate 1500mg

Granules for oral solution

COMPOSITION:

Each 4g sachet of granules for oral solution contains:

Meloxicam …………………………………………. ….. 15 mg

Glucosamine Sulfate Potassium Chloride …… 1990 mg

(Equivalent to 1500 mg of Glucosamine Sulfate)

USES AND ADMINISTRATION

The pharmacological properties of glucosamine sulphate explain its beneficial activity in the degenerative and dismetabolic processes of osteoarthritis and in particular on the symptoms of the disease in different locations.

The administration of glucosamine sulfate allows to supplement the endogenous deficiencies of this substance, thus stimulating the biosynthesis and inhibiting the degradation of the proteoglycans, necessary to achieve a trophic effect in the articular facets, favor the fixation of sulfur in the synthesis of chondroitin sulphuric acid and facilitate the normal deposit of calcium in the bone tissue.

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) belonging to the group of enolcarboxamides. By inhibiting cyclooxygenase, locally prevents the conversion of arachidonic acid into cyclic endoperoxides, which are transformed into prostaglandins, thromboxanes and inflammation mediators circulating autacoids and eicosanoids. By inhibiting cyclooxygenase and the subsequent synthesis of prostaglandins, the release of proinflammatory substances and mediators is reduced, preventing the activation of the terminal nociceptors.

The chondroprotective and repairing effect of glucosamine, combined with the analgesic and anti-inflammatory action of meloxicam, significantly alleviates pain at rest and movement, improving mobility in the short and medium term.

INDICATIONS:

Symptomatic treatment of osteoarthritis (osteoarthrosis – osteoarthritis) and other articular and extra-articular rheumatic diseases.

HOW TO USE:

In a glass of boiled and cold water, pour the contents of an envelope, shake and drink once a day, preferably with breakfast

CONTRAINDICATIONS:

• Hypersensitivity to any of the formula’s components.

• Severe hypersensitivity to other NSAIDs.

• Phenylketonuria.

“Contraindicated in pregnancy or when its existence is supposed”

“Contraindicated in cases of gastritis, ulcers and / or gastroduodenal hemorrhages”

ADVERSE EFFECTS:

Meloxicam:

• Gastrointestinal: Occasionally: dyspepsia, nausea, vomiting, abdominal pain,

constipation, flatulence and diarrhea. Rarely: transient alteration of liver function parameters, (hepatic enzymes, increased bilirubin), belching, esophagitis, gastroduodenal ulcer, occult or macroscopic gastrointestinal bleeding.

• Glucosamine sulfate:

The side effects of glucosamine sulfate are uncommon and generally of a mild and transient nature. On rare occasions, the onset of nausea, heaviness, abdominal pain, bloating, constipation, diarrhea, dizziness, drowsiness and headache has been described. Hypersensitivity reactions: erythema, pruritus or bronchial asthma have been reported with low incidence

COMPOSITION: Each tablet contains: 250 mg of vitamin B12, excipients, qs 1 tablet.

INDICATIONS: The B vitamins are essential for the metabolism of carbohydrates, proteins and fats, they are needed for blood formation and are very important for skin, mucous membranes, nervous system, cardiovascular system, muscles. COMPLEJO B® FORTE is indicated for the prevention and treatment of specific deficiency of thiamine, pyridoxine and cyanocobalamin deficiency caused by dietary intake or in conditions which daily requirements are increased such as pregnancy, lactation, alcoholism, fever, induced by other drugs, specific metabolic disorders, deficiencies of other components of the B complex, vegetarian diets, neuritis, anemia, fatigue and vomiting during pregnancy, liver dysfunction.

DOSE: Adults: TREATMENT: 3 to 4 tablets of COMPLEJO B® FORTE daily. Treatment duration will depend on the therapeutic response and can be used continuously without exceeding 3 months. 1 tablet daily. PREGNANCY: 1 tablet daily.

PREVENTION:

ADMINISTRATION: Tablets of COMPLEJO B® FORTE should be administered orally with enough water.

CONTRAINDICATIONS: There are no contraindications to the specified limits.

PRECAUTIONS: Cyanocobalamin should not be administered without first confirming the diagnosis of megaloblastic anemia. INTERACTIONS: no clinically significant.

INTERACCIONES: Ninguna con significado clínico.

PREGNANCY AND LACTATION: Can be used in both conditions.

ADVERSE REACTIONS: The long term administration of high doses of thiamin can lead to neurotoxicity.

COMPOSITION: Each tablet contains 200 mg and 400 mg Ofloxacin. Excipients c.s.p. Ofloxacin is aquinolone with broad-spectrum bactericidal action.

INDICATIONS: UROSTAT® is indicated for the treatment of adults with infections caused by susceptible strains. It has been used in the treatment of a wide range of infections: acute gonorrhea, uncomplicated urethral and cervical cancer. Non-gonococcal urethritis and cervicitis. Mixed infections of the urethra and cervix due to Chlamydia trachomatis and Neisseriagonorrhoeae. Acute pelvic inflammatory disease. Uncomplicated cystitis and complex urinary tract infections. Prostatitis: other infections: Acute bacterial exacerbation of chronic bronchitis and community-acquired pneumonia, uncomplicated infections of the skin and its annexes.

DOSAGE AND ADMINISTRATION: Ofloxacin is administered orally. The usual adult dose is 200 to 400 mg every 12 hours in patients with normal renal function.

SIDE EFFECTS: The most frequently reported adverse effects related to the drug are nausea, insomnia, headache, dizziness, diarrhea, vomiting, rash, pruritus, external genital pruritus in women, vaginitis, dysgeusia.

PRECAUTIONS: In patients with epilepsy or history of CNS diseases. In patients with impaired liver or kidney functions. Avoid drinking alcohol. You can interact with oral hypoglycemic agents or insulin, antacids, iron preparations, opioids, theophylline and warfarin. Pregnancy: Category C.

CONTRAINDICATIONS: Not recommended for children and adolescents, pregnant women and nursing mothers.

COMPOSITION: Each tablet contains ketoconazole + Secnidazole 250 mg, excipients qs 1 tablet.

INDICATIONS: MICOSIN® PLUS is indicated for the treatment of vulvovaginal and urethral infections produced by single or mixed Tricomonasvaginalis. Candidaalbicans and Gardnerellavaginalis.

DOSE: Trichomonasvaginalis urethritis and vaginitis: Bacterial vaginosis: (Gardnerellavaginalis vaginitis) and vulvovaginal candidiasis balanitis Candidaalbicans; Adults: 1 tablet of PLUSMICOSIN® PLUS twice daily preferably with meals for 5 days. Should be treated simultaneously with the sexual partner. During treatment the male partner should use condoms.

ADMINISTRATION: MICOSIN® PLUS should be administered orally with enough water, along with breakfast and dinner to promote absorption of active ingredients.

CONTRAINDICATIONS: PLUSMICOSIN® PLUS is contraindicated in patients with a history of hypersensitivity to nitro imidazole derivatives or other Secnidazole and ketoconazole. It is contraindicated during pregnancy and lactation. Administration of MICOSIN R PLUS is contraindicated with the following medications: alfentanil, astemizole, terfenadine, midazolam and triazolam, cisapride, cyclosporine, paclitaxel, pimozide, quinidine, sertindole, sildenafil, lovastatin and simvanstine.

PRECAUTIONS: MICOSIN® PLUS should be used with caution in patients with blood dyscrasias (leukopenia may occur) or with active disease of the central nervous system (including epilepsy) and in patients with preexisting liver disease.

INTERACTIONS: See Contraindications: With alcohol can cause a disulfiram-like reaction, so you should avoid alcohol (including medicines that contain alcohol) during treatment and for a few days after completion. Increases the anticoagulant effect of warfarin.

PREGNANCY AND LACTATION: It is contraindicated during pregnancy and lactation.

SIDE EFFECTS: They are rarely severe enough to discontinue treatment. The most common are gastrointestinal distress such as nausea, sometimes together with headache, anorexia, dyspepsia, nausea and vomiting, unpleasant metallic taste. Occasional diarrhea, dry mouth, coated tongue, glossitis, stomatitis. Peripheral neuropathy (numbness or hypoesthesia in limbs), and seizures, transient increase of liver enzymes have rarely been reported.

COMPOSITION: Each tablet contains: Iron Polymaltosed: 100 mg, excipients c.s.p. 1 tablet. Each mL of syrup contains: Iron polymaltosed: 50 mg; drops each mL contains: Iron Polymaltosed: 50 mg.

INDICATIONS: FERRUMKLINGE® is indicated for the treatment and prophylaxis of iron deficiency anemia and iron deficiency states due to increased demand, pregnancy, rapid postnatal growth phase, growth phase during adolescence, or pathological loss: gastrointestinal hemorrhage gynecological surgery. Insufficient absorption, lack of intake (elderly, strict vegetarians).

DOSE: Adults: for treatment of iron deficiency anemia, the usual dose is 100-200 mg of iron (2 to 4 mL or 40 to 80 drops) to normalize the concentration of hemoglobin (10 weeks). The prophylactic dose is 60 to 120 mg / day of iron (24 to 48 drops) to replenish reserves (3-6 months). Children: Treatment: 2 mg / kg body weight 3 times a day. Prophylaxis: 1 mg / kg / day. The dose and duration of treatment depend on the degree of iron deficiency. In pregnant women the dose prophylactic treatment should continue until the end of gestation.

COMPOSITION: Each tablet contains 300 mg of lithium carbonate and excipients qs 1 tablet.

INDICATIONS: Prophylaxis and treatment of manic and acute hypomanic episodes. In bipolar illness. Prophylaxis of recurrent unipolar depressive disorders. In schizoaffective and neuroleptics disorders. To control aggressive behavior or self-mutilating. Treatment of adolescents with bipolar disorder, childhood aggression and behavioral disorders associated with mental retardation and developmental disorders.

Nonpsychiatric Use: Prophylaxis for some forms of migraines and headaches. Treatment of spontaneous leukopenia or induced by chemotherapy.

DOSAGE: The dose varies between 600 and 3,000 mg per day administered 2-3 fractions per day. The therapeutic efficacy is achieved with serum levels between 0.4 to 1 mmol / L. The therapeutic concentrations must be adjusted individually for each patient, to those that produce clinical response without evidence of toxicity. The lithemia should be performed regularly.

PRECAUTIONS: The margin between therapeutic and toxic concentration is narrow, therefore, it should be administered under medical supervision.
Before prescribing Ceglution 300 it is recommended to do a renal function and thyroid tests. When the patient is older than 40 or has a cardiac history it is advised to conduct an EKG

CONTRAINDICATIONS: Severe renal or cardiovascular ailments. Metabolic disorders. Debilitated or dehydrated patients with hyponatremia and Addison’s disease, as well as concomitant use of diuretics. In pregnancy only if judged clinically required. Contraindicated during lactation.

COMPPOSITION: Gotas: Drops: Each 100 mL contains: Clorofennotiazinilscopina Hydrochloride, 2.5 g.  Each tablet contains 200 mg: clorofenotiazinilcopine hydrochloride, 25 mg, excipients, c.s.p. 1 tablet.

INDICATIONS: disorders that have nausea and vomiting as prominent features, common vomiting or pregnancy, hyperemesis gravidarum, vomiting induced by drugs. Motion sickness.

DOSE: Adults: 10 25 mg c/4 to 6 hours (8 ½ to 20 drops or 1 tablet c/ 4 to 6 hours. Infants and children: 0,5 / kg bw c/4 6 hours. Children of 1 to 5 years: Maximum dose: 40 mg / day (10 drops or ½ tablet 3 times daily). Children > 5 years: Maximum dose: 75 mg / day (20 drops or 1 tablet 3 times daily).

CONTRAINDICATIONS AND PRECAUTIONS: Hypersensitivity to the active, CNB depression, bone marrow depression. Pheochromocytoma. Avoid concomitant use with alcohol.